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Purpose/Objective: Transrectal Ultrasound (US) is the standard 
imaging modality for High-Dose-Rate brachytherapy (HDR-BT) in 
prostate cancer. The treatment is most often delivered with the US 
probe positioned in the rectum, in order to maintain the same patient 
set-up as during the US treatment planning. However, it is an open 
question whether removal of the probe before HDR-BT delivery may 
be an advantage in terms of rectal dose. The objective of this study 
was to compare rectum dose with and without the US probe in place. 
Materials and Methods: T2-weighted (T2W)-MRI based HDR-BT 
treatment planning was performed after transrectal US guided needle 
implantation for 6 fractions of HDR-BT in 3 prostate cancer patients. 
HDR-BT was delivered in 2 fractions of each 8.5 Gy preceded by 46 Gy 
given in 23 fractions of external beam radiotherapy (EBRT). T2W-MRIs 
and US images were co-registered based on the HDR-BT needle 
implant (figure 1). The same optimized treatment plan based on MRI 
contouring was applied on both MR- and US images. Rectum dose-
volume parameters were evaluated for the 2 scenarios; 1) with the US 
probe in place (US images) and 2) with the US probe removed (MR 
images). Doses were evaluated as the total EBRT+BT EQD2 (α/β = 3 for 
rectum). Furthermore, absolute volumes irradiated to at least 70 Gy 
and 60 Gy (total EBRT+BT) were evaluated. 
 
 
Results: The mean rectum doses D5cm3, D2cm3 and D0.1cm3 were 
consistently higher for the case where the US probe was present in the 
rectum during the HDR-BT delivery (increase of 4, 5 and 13 Gy, 
respectively) (table 1). Furthermore, V70Gy (probe in: 2.2 ± 1.1 Gy; 
probe out: 0.8 ± 0.5 Gy) and V60Gy (probe in: 8.7 ± 1.8 Gy; probe out: 
4.7 ± 1.4 Gy) decreased when the US probe was removed. Qualitative 
evaluation of the rectal anatomy with (US) and without (MR) probe 
indicated that the distance between prostate and rectum was 
increased at the base- as well as at the apex regions after removal of 
the US probe (figure 1). 
 
  
Conclusions: Our results indicate that by removing the US probe from 
the patient during the delivery of HDR-BT the dose to rectum can be 
reduced. This study did not evaluate potential deformations of target 
and consequential impact on target dose induced by the US probe 
removal. The advantages of decreased rectal dose by probe removal 
may compromise target dose in the setting of US guided prostate HDR-
BT and should be further evaluated. 
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Purpose/Objective: LDR prostate brachytherapy using permanent 
iodine125 seeds has been offered to men with low volume prostate 
cancer in Wellington since 2001, and 500 men had been treated with 
145Gy by 2010. 
Materials and Methods: We initially employed the treatment 
technique as developed and reported by the Seattle Prostate 
Institute. Dose distribution based on a post-implant pelvic CT scan at 
4-6 weeks was routinely calculated for quality assurance purposes, 
and perceived deficiencies in dosimetry led to modifications in the 
way we planned and positioned future implants. Adjustments included 
a gradual reduction in margins as the implants improved technically, 
and changes in seed distribution to prevent crowding of seeds at the 
prostate apex. 
Results: Median follow up was 34 months (range 1-119 months). 23 
men developed biochemical failure (BF), and only two of these had 
detectable local failure. The risk of BF at 5 years was 6.7%. The only 
tumour characteristic that predicted a significantly higher chance of 
BF was an initial PSA > 10, whereas Gleason score, clinical stage, and 
percentage positive biopsies were not predictive. The D90 (<90, 90-
125, >125) had no detectable effect on the risk of BF. There have 
been 11 deaths in total, but only two from prostate cancer. 
There were 26 grade three side effects. Acute (within six months) 
grade three side effects were largely urinary, with 20 men (4%) 
requiring temporary urinary catheterisation. There was one case of 
protracted rectal ulceration. Delayed grade three side effects were 
defined as those occurring after 6 months that required operative 
intervention. There were three cases of urethral stricture, and two of 
chronic rectal ulceration, one leading to the development of a recto-
urethral fistula. The risk of any grade three side effect was 
independent of the D90 (<90, 90-125, >125) and the V150 (<40, 40-65, 
>65). The V150 was >65 in 56 (11%) implants. 
155 men (31%) required a PDE5 inhibitor for erectile dysfunction after 
their implant (but not before) and only 62 (11%) found this treatment 
ineffective. The risk of erectile dysfunction was not affected by the 
V150 (<40, 40-65, >65) and younger men (≤60 years) were not at 
significantly lower risk of this side effect. 
Conclusions: Biochemical control and toxicity in this series are at 
least as good as those reported elsewhere.  
A low D90 & V150 did not predict for an increased chance of BF, as 
some series have shown. This is possibly due to there being too few 
events (23) in our series to allow meaningful statistical comparisons 
involving small sub-groups (<90 D90; 70 [14%] implants, and <40 V150; 
73 [14.6%] implants). Inaccuracies in defining the prostate volume on 
CT may have been a factor, but it is also possible that the dose-effect 
range for low volume cancer is below the minimum dose achieved 
with the great majority of implants. High D90 and V150 did not 
predict for an increased risk of grade 3 toxicity, similar to other 
reported series. Side effect risk may be more a function of the 
prostate size, baseline urinary symptoms and implant technique rather 
than the dose distribution achieved by the implant.  
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Purpose/Objective: To determine whether dosimetric parameters, 
biochemical control of prostate cancer and late toxicity in patients 
with large prostate glands is different to those with smaller sized 
glands after treatment with high dose-rate brachytherapy alone (HDR-
BT). 
Materials and Methods: From November 2003 to July 2009, 164 
patients with locally advanced prostate carcinoma were sequentially 
enrolled and treated with 34 or 36 Gy (in 4 fractions) and 31.5 Gy (in 3 
fractions) of 192Ir HDR-BT alone. Median follow up is 71 months. 
Prostate gland size was not considered a selection criteria in this 
study. Estimates of freedom from biochemical relapse (FFbR) and late 
morbidity, stratified by median clinical target volume (CTV), were 
obtained using the Kaplan-Meier method and differences compared 
using the Mantel-Cox log-rank test. Hazard Ratios were obtained using 
Cox’s Proportional Hazard Model. Differences in IPSS scores grouped 
by median CTV were compared using Fisher's Exact Test (2-tail p). 
Results: Median CTV volume was 60 cc (range 15 to 208 cc). Dose-
volume parameters D90 and V100 (i.e. minimum dose to 90% of the 
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prostate volume and volume that received 100% of the prescribed iso-
dose, respectively) achieved in glands ≥ 60 cc were not significantly 
different compared to those with glands < 60 cc (p≥ 0.2). Nonetheless, 
biochemical control of disease in patients with larger CTV was 
significantly higher (91% vs 78% at 6 years; p = 0.004). In uni and 
multivariate analysis, CTV was a significant predictor for risk of 
biochemical relapse. This was not at the expense of an increase in 
either moderate (p = 0.6) or severe (p = 0.3) late genitourinary 
toxicity. Usage of hormonal therapy was 17% lower in the large gland 
group (p = 0.01). There was no significant difference in FFbR or in the 
incidence of late genitourinary or rectal morbidity between the three 
fractionation schedules. 
 
  
Conclusions: Prostate gland size does not affect dosimetric 
parameters in HDR-BT assessed by D90 and V100. In patients with 
larger prostate glands a significantly higher biochemical control of 
disease has been observed with no difference in late toxicity. This 
improvement cannot be attributed to differences in dosimetry. Gland 
size should not be considered when selecting patients for HDR-BT.  
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Purpose/Objective: Even though calcifications are observed in clinical 
practice, the actual dose calculation algorithm (TG-43) overrides 
them with water material and density. However, it is a known fact 
that at low energy in LDR seed implants the cross section depends 
strongly on the effective atomic number, increasing the probability of 
important dose discrepancies around the calcified regions. It is 
hypothesized that significant effects on the dose metrics such as the 
dose volume histogram (DVH), target volume and urethra are not 
taken into accounts. This study investigates these effects on delivered 
dose from calcifications in post-implant dosimetry.  
Materials and Methods: 42 patients with visible calcifications in the 
prostate were identified. Threshold segmentation is used to 
distinguish normal prostate tissue from calcification. Monte Carlo (MC) 
simulations are made with the Geant4-based ALGEBRA software [1] in 
1mm3 voxels. Materials are assigned based on TG-186 recom-
mendations and the sources are explicitly modeled. Breast 
calcification definition is used to define the prostate calcification with 
density taken from the CT numbers. We identified 6 different dose 
calculation scenarios for our study: MC in water with (1) and without 
(2) seeds, 2) MC in a water prostate with densities from the CT but 
with calcification areas with (3) and without seeds (4) and finally full 
tissue heterogeneities with (5) and without seeds (6).  
Results: Relative to the TG-43 algorithm, we measure large 
differences, up to -27 (-28)% on the D90 (V100) with full tissue 
heterogeneities and seeds modeled, and up to -25 (-22)% when only 
the calcificified areas and seeds are taken into account. The negative 
sign indicated a decrease in dose relative to TG-43. Calcifications, 
inter-seed attenuation and tissue heterogeneities can lead to 
interplay phenomena. Hot-spot regions as defined by V200 are the 
most affected, with difference to TG-43 up to -74%. The urethra also 
shows significant dose discrepancies depending on the location of the 
calcifications. Urethra D90 differences of -17% relative to full MC 
calculations are observed, -10% considering calcification only. For all 
cases under investigation, the average decrease of D90 is -15% for the 
prostate and -8% for the urethra.  
Conclusions: Taking into account tissue heterogeneities, composition, 
and calcifications composition produces the highest change relative to 
TG-43. Based on the patient cohort, calcifications have a measurable 
impact on the target volume dose parameters and also may bring a 
significant decrease in the delivered dose to the urethra. The real 
composition of the prostate calcification remains to be determined to 
establish a better understanding ofthe dosimetric consequences. 
[1] Afsharpour, et al, 'ALGEBRA: ALgorithm for the Heterogeneous 
Dosimetry Based on GEANT4 for BRAchytherapy.' Physics in Medicine 
andBiology 57, no. 11 (June 7, 2012): 3273–3280.doi:10.1088/0031-
9155/57/11/3273. 
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Purpose/Objective: MRI provides the gold standard for tumour 
delineation in gynaecological brachytherapy. While traditionally CT 
has been used for applicator reconstruction and then fused with MRI, 
in recent years the use of MRI only for the reconstruction of 
applicators, with or without MRI compatible line markers, has become 
more widespread. The purpose of this study is to evaluate the inter-
operator differences in DVH parameters for OAR and HR-CTV when 
reconstructing titanium applicators with a fixed geometry, based only 
on T2 MRI images. Line markers are not currently commercially 
available for this applicator type. GEC-ESTRO recommendations 
regarding HR-CTV were followed and identical library plans used, 
prescribing to point A. 
Materials and Methods: Three patient plans using an identical OAR 
and HR-CTV structure set were used to retrospectively reconstruct a 
titanium Rotterdam type applicator using a 3D library model. Eight 
regular planners (radiographers, medical physicists and dosimetrists) 
independently reconstructed applicators and set an origin point based 
upon the applicator model. Identical library plans were loaded onto 
each applicator and the variations in DVH parameters for both HR-CTV 
and OAR assessed. 
Results: Co-ordinate positions of point A were used as a surrogate for 
applicator model alignment to the applicator image. Vector 
differences between eight regular planners were assessed by 
comparing the average co-ordinates of point A between all of the 
plans. The vector differences between the co-ordinates, compared 
against the average co-ordinates, show that the mean absolute 
difference between planners is 1.0mm (SD 0.4mm). All values were 
within 2mm, which shows good agreement between planners.  
The average percentage absolute-differences in DVH parameters 
arising from these variations, when compared against the average 
value for each, can be seen in Table 1. 
 
Table 1 
These results show that the average absolute differences are very low 
(<=3.3%), with the highest difference being for the HR-CTV D100%, 
which is known to be less reproducible than the D98% for HR-CTV.  
 
  
